Log In
BCIQ
Print this Print this
 

MicOryx

  Manage Alerts
Collapse Summary General Information
Company Oryx GmbH & Co. KG
DescriptionVaccine comprised of 3 synthetic frameshift peptides: AIM2, HT001 and TAF1B
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationColorectal cancer
Indication DetailsTreat advanced microsatellite instable (MSI-H) colorectal cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today